Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Acquires 125,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 125,000 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were purchased at an average price of $1.59 per share, for a total transaction of $198,750.00. Following the completion of the transaction, the chief executive officer now directly owns 212,536,477 shares in the company, valued at approximately $337,932,998.43. This trade represents a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, December 11th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.56 per share, for a total transaction of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost acquired 199,072 shares of OPKO Health stock. The stock was acquired at an average cost of $1.53 per share, with a total value of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.59 per share, for a total transaction of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The stock was acquired at an average price of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost acquired 280,183 shares of OPKO Health stock. The shares were bought at an average price of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Price Performance

OPK stock traded down $0.02 during trading on Friday, hitting $1.59. 3,044,472 shares of the company’s stock traded hands, compared to its average volume of 6,804,103. OPKO Health, Inc. has a 52 week low of $0.85 and a 52 week high of $1.76. The business has a fifty day simple moving average of $1.53 and a 200 day simple moving average of $1.47. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on OPK. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a research note on Tuesday, September 17th. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a report on Friday, November 8th. Finally, HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in OPK. CIBC Asset Management Inc increased its stake in OPKO Health by 79.1% during the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 8,978 shares during the last quarter. FMR LLC boosted its holdings in shares of OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the period. Orion Portfolio Solutions LLC bought a new position in shares of OPKO Health during the 3rd quarter valued at approximately $45,000. Algert Global LLC purchased a new stake in OPKO Health during the 2nd quarter valued at $44,000. Finally, Private Advisor Group LLC lifted its position in OPKO Health by 242.7% in the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock worth $53,000 after buying an additional 25,000 shares during the last quarter. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.